This difference in results highlighted the necessity of antiangiogenic agents and supported the hypothesis that antiangiogenic agents could enhance immune efficacy, which might be due to the remarkable improvement of antigen-specific T-cell migration, in patients with NSCLC with EGFR mutations in response to antiangiogenic treatment (25). This evidence concerns the gene EGFR and non-small cell lung carcinoma.